News and Press Releases
Press releases
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Press Release, Bladder Cancer, Clinical Study, NMIBCToronto, Ontario – January 15th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or r...
Theralase Release’s 3Q2023 Interim Financial Statements
Press ReleaseToronto, Ontario – November 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/o...
Theralase® Closes $CAN 1.17 Million Non-Brokered Private Placement
Press ReleaseNovember 29, 2023, Theralase® successfully closed a non-brokered private placement offering of units for gross proceeds of approximately $CAN 1,170,000....
Theralase® Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Press ReleaseToronto, Ontario – November 17, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or ...
Theralase® Announces Brokered LIFE Financing
Press ReleaseToronto, Ontario – October 23, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or r...
Theralase® Provides Update on Bladder Cancer Clinical Study
Press ReleaseTheralase®’s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®’s Anti-Cancer Therapy Achieved a Complete Response Toronto, Ontario – October 16, 2023, Theralase® Technologies Inc. (“Theralase®” or th...
Theralase® Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar™
Press ReleaseToronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of li...
Theralase® Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Press ReleaseToronto, Ontario – September 27, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of li...
Theralase® Grants Stock Options
Press ReleaseToronto, Ontario – September 21, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activa...
Theralase Release’s 2Q2023 Interim Financial Statements
Press ReleaseToronto, Ontario – August 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
